DAPA-HF: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

DAPA-HF: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes were lower among those who received dapagliflozin than among those who received placebo, regardless of their diabetes status.

Rationale

Reference

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008.

>